Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2

Episode 2 • October 21, 2021 • 00:18:13
Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2
COR2ED Medical Education
Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2

Oct 21 2021 | 00:18:13

/

Show Notes

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.

This second episode focuses on recent developments in immunotherapy approaches in metastatic colorectal and gastric cancer – specifically whether immunotherapy should be used alone, in combination with other treatments or with chemotherapy. Data from several clinical trials are discussed such as KEYNOTE-177, CheckMate 142, CheckMate 649, KEYNOTE 062, and NICHE. The experts also consider the appropriate treatment regimens for MSI-high and MSS colorectal and gastric cancer patients and whether CPS is an appropriate biomarker for gastric cancer.

Other Episodes

Episode 3

March 27, 2023 • 00:22:49
Episode Cover

Overview of efficacy and safety data of combination therapy with PARPi and NHAs

Overview of efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented and the impact for the treatment...

Listen

Episode

November 21, 2023 • 00:29:54
Episode Cover

Prostate Cancer: Pre-Analytical Phase Challenges and Biomarker Testing

What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?...

Listen

Episode 1

November 18, 2022 • 00:32:39
Episode Cover

The role of SSA at progression – to continue or not?

COR2ED Medical Education: In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether...

Listen